WallStSmart

Boston Scientific Corp (BSX)vsCarMax Inc (KMX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CarMax Inc generates 35% more annual revenue ($27.76B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 0.9%. KMX appears more attractively valued with a PEG of 0.38. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

KMX

Buy

52

out of 100

Grade: C-

Growth: 2.0Profit: 4.0Value: 8.7Quality: 4.5
Piotroski: 3/9Altman Z: 1.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-16.7%)

Margin of Safety

-16.7%

Fair Value

$46.22

Current Price

$53.93

$7.71 premium

UndervaluedFair: $46.22Overvalued
KMXUndervalued (+83.0%)

Margin of Safety

+83.0%

Fair Value

$270.07

Current Price

$40.34

$229.73 discount

UndervaluedFair: $270.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

KMX2 strengths · Avg: 10.0/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

KMX4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.534/10

Distress zone — elevated risk

Return on EquityProfitability
4.1%3/10

ROE of 4.1% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

Operating MarginProfitability
1.8%3/10

Operating margin of 1.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : KMX

The strongest argument for KMX centers on PEG Ratio, Price/Book. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : KMX

The primary concerns for KMX are Altman Z-Score, Return on Equity, Profit Margin. Debt-to-equity of 2.75 is elevated, increasing financial risk. Thin 0.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

BSX profiles as a mature stock while KMX is a value play — different risk/reward profiles.

KMX carries more volatility with a beta of 1.18 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 52/100), backed by strong 17.3% margins and 11.6% revenue growth. KMX offers better value entry with a 83.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

CarMax Inc

CONSUMER CYCLICAL · AUTO & TRUCK DEALERSHIPS · USA

CarMax is a used vehicle retailer based in the United States. It operates two business segments: CarMax Sales Operations and CarMax Auto Finance.

Visit Website →

Want to dig deeper into these stocks?